Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus

Lupus

Volumn 19, Issue 10, 2010, Pages 1256-1257

  Faria, R M ^a   Isenberg, D A ^b  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; RITUXIMAB;

ADULT; ANEMIA; ANTIBODY RESPONSE; ARTERIAL INSUFFICIENCY; B LYMPHOCYTE; CASE REPORT; COOMBS POSITIVE HEMOLYTIC ANEMIA; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GLOMERULONEPHRITIS; HEMOLYSIS; HUMAN; HYPERSENSITIVITY REACTION; INFLAMMATION; KIDNEY FAILURE; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; PERITONITIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; SEPTIC SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTOPENIA; VASCULITIC RASH;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; YOUNG ADULT;

EID: 77956236829     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310373107     Document Type: Letter

References (3)

1. Tahir H., Rohrer J., Bhatia A., Wegener WA, Isenberg DA Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology 2005 ; 44: 561-562.
2. Stein R., Qu Z., Chen S., et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004 ; 10: 2868-2878.
3. Mojcik AF, Klippel JH End-stage renal disease and systemic lupus erythematosus. Am J Med 1996 ; 101: 100-107.